Latest Medical Devices News

OncoSil Medical secures a spot in the PALACROS consortium, advancing its OncoSil™ device through a cost-efficient Phase II trial targeting unresectable locally advanced pancreatic cancer.

Imricor Medical Systems expands its US market reach with FDA 510(k) clearances for pediatric use of its NorthStar system and Vision-MR Diagnostic Catheter, enabling radiation-free cardiac catheterisations for children.

Saluda Medical has obtained FDA approval for its CAP24 surgical paddle lead, a first-of-its-kind device designed for closed-loop spinal cord stimulation, poised to broaden its US market reach and engage new surgical specialties.

CONNEQT Health Limited is offering eligible shareholders a share purchase plan to raise up to $0.5 million at a 24.3% discount, aiming to fund its next growth phase in vascular health technology.

Truscreen Group has issued nearly 150 million new shares at NZ$0.013 each, expanding its share base by 17.4% following a renounceable rights issue. The fully paid shares rank equally with existing stock, lifting total ordinary shares to just over one billion.

Adherium Limited has obtained a USD 1.65 million short-term unsecured loan from its major shareholder, Trudell Medical, to fund immediate working capital needs while pursuing capital structure adjustments.

TruScreen Group posted a NZ$2.25 million loss for FY2026, with its auditor highlighting material uncertainty over the company’s ability to continue without further funding. Revenue rose to NZ$2.4 million amid geographic expansion, but cash burn and accumulated losses remain significant.

TruScreen Group has completed a substantially oversubscribed NZ$2.9 million rights issue, boosting total capital raised to over NZ$4 million. The funds are set to support the company’s global expansion in cervical screening technology.

EBR Systems has wrapped up the retail tranche of its fully underwritten entitlement offer, adding A$10.9 million to a total raise of about A$43.6 million to support its wireless cardiac pacing technology.

CONNEQT Health has lodged an FDA Pre-Submission for SphygmoCor Cloud, aiming to shift its arterial health analytics from hardware to a scalable software platform with broad commercial potential.

CONNEQT Health has raised A$5.5 million through a two-tranche placement at a 15.4% discount, backed by key shareholders, to accelerate its commercial expansion and product development.

Vitrafy Life Sciences has secured A$30 million through an institutional placement to ramp up manufacturing of its Guardion cryopreservation devices and expand US sales operations, with an additional A$2 million sought via a shareholder plan.